Quanterix

Our Quanterix team members Amy Hinds and Carly Trulock-Quinn were on-site this week at #AAN with American Academy of Neurology, connecting with clinicians, researchers, and industry leaders who are all pushing the boundaries of what’s possible in #neurology. The energy around blood-based diagnostics and precision medicine continues to grow — and we’re excited to be a part of that momentum. #AAN2025

#News Simoa® is Bringing Blood-Based Biomarkers to the Forefront   At AD/PD 2025 last week, NeurologyLive sat down with Mark Roskey, PhD, chief scientific officer at Quanterix, to discuss our Simoa technology, its function, and role in the diagnosis of AD.    Read the full interview here: https://lnkd.in/e6fzp6qR   Our Simoa technology was featured in over 80 posters, presentations, and sessions at AD/PD 2025, delivering the gold standard for earlier biomarker detection in blood, serum, or plasma, with the ability to quantify proteins that are far lower than the level of quantification.    #biomarkers #alzheimersdisease #ADPD2025

Thanks to all who attended our seminar today with Victor Lopez and Danilo La Terra. Our sales and field application science team host seminars all over the world - if you would like to host an event on biomarker research using Simoa, reach out!

It's time to unravel inflammation in #neurological disorders with ultra-sensitivity. Read our app note to discover how the Simoa® Cytokine Advantage PLUS Assays offer an ultrasensitive, fully automated solution for #cytokine measurement, providing the scalability and reliability needed to accelerate both research and clinical applications in disorders such as traumatic brain injury, neurodegenerative diseases, and psychiatric conditions. Measuring cytokines--the key mediators and #biomarkers of the pathophysiology of these disorders--can provide valuable insights into disease mechanisms, aid in diagnosis and prognosis, and inform treatment strategies overall. Learn more: https://lnkd.in/esa6CttR

Meet Quanterix at The 3rd Swedish Meeting for Alzheimer Research on April 10 in Stockholm! Organized by the Center for Alzheimer Research, Karolinska Institutet, join us for a jam-packed day focused on research on Alzheimer's disease and related disorders. The conference brings together researchers from all of Sweden as well as clinicians and industry partners related to the topic of dementia. Be sure to catch Canan Ugur-Yilmaz, PhD, as she discusses ®Simoa Technology: Unlocking New Insights in Alzheimer's Disease Through Ultrasensitive Biomarker Detection in an interactive presentation at 12:15. 🕛 Date/Time: Thursday, April 10 at 12:15 📍 Location: Stockholm, Sweden We look forward to connecting with you! #swedishmeeting #alzheimersresearch

Wrapping up an inspiring week at #ADPD2025 — and we’re leaving Vienna more energized than ever. From groundbreaking science to powerful conversations, this year’s conference underscored the growing momentum behind blood-based biomarkers in Alzheimer’s research. One standout session demonstrated that MTBR-tau243, when measured using Simoa®, remains a promising treatment response biomarker—despite challenges seen in PET imaging and clinical endpoints. Sensitive detection of tau species in CSF and plasma is reshaping how we assess drug effects and understand disease progression. Another key presentation highlighted the predictive power of biological age and epigenetic clocks in Alzheimer’s risk—especially in underrepresented populations. Findings like these are moving the field toward more personalized, inclusive diagnostics. We also hosted three final in-booth talks, covering everything from blood biomarkers in dementia to cardiovascular risk and plasma biomarker correlations. A huge thank you to our speakers and all who engaged with us throughout the week. At Quanterix, we’re proud to support the research community with tools that unlock deeper understanding and drive real-world impact. Here’s to what’s next. #AlzheimersResearch #Neurodegeneration #Biomarkers

#News A recent study highlighted the consistent performance of Simoa® in quantifying NfL, offering a reliable tool for ALS diagnosis and prognosis. NfL’s high sensitivity and predictive value make it a promising biomarker for wider clinical implementation. Evaluations included the diagnostic and prognostic value of NfL, GFAP, and pTau181 biomarkers in ALS, revealing that NfL offered high diagnostic and prognostic accuracy, while GFAP and pTau181 demonstrated poor diagnostic value. Read more: https://lnkd.in/eg86Vqmw #neurofilament #biomarkers #als

We’re wrapping up day 4 of #ADPD25 and today’s sessions made one thing clear: precision + inclusivity = the future of Alzheimer’s diagnostics. In one standout study, plasma SNAP25 — once thought CSF-only — was reliably measured using Simoa®, showing an AUC of 80%, rising to 92% when paired with p-tau217. Non-invasive, high-performance diagnostics are closer than ever. Another important session explored diabetes and ethnicity in biomarker expression. Using Simoa to measure NfL, GFAP, Aβ40/42, and p-tau181, researchers found key differences across Hispanic/Latino populations — a powerful call for more diverse validation. At our booth, we hosted presentations from: • Mathias Sauer (Univ. of Gothenburg) on a novel NPTX2 assay • Suvi Rovio (Univ. of Turku) on the gut-brain link (MicroCOGNI study) • Elisabeth Thijssen, PhD (Neurogen Biomarking) on scalable early AD detection From lab to life — Quanterix is proud to power the tools driving real-world impact. #ADPD2025 #AlzheimersResearch #BloodBiomarkers

Day 3 at AD/PD 2025 spotlighted sex-specific science in Alzheimer’s disease — and the insights are game-changing. Women face nearly 2x the AD risk by age 60, and we're finally uncovering why. New data show that female ApoE4 carriers experience elevated IL-17F–driven inflammation, fueling microglial activation and cognitive decline. The upside? IL-17F inhibition shows promise in reducing neuroinflammation and improving outcomes. Tools like Simoa® are critical in detecting these subtle biomarker shifts — measuring inflammation, injury, and immune signals with unmatched sensitivity. Precision neurology depends on understanding sex-specific pathways. We're moving beyond observation — we're decoding disease. Learn more about #ADPD2025 in our daily blog recap: https://lnkd.in/egxx6EUU #AlzheimersResearch #Biomarkers #PrecisionMedicine #WomenInScience

Brain disease research has been revolutionized. The Simoa® digital immunoassay technology is highly sensitive when detecting CNS biomarkers in blood--up to 1000-times greater sensitivity than traditional analog ELISA technology--providing reliable quantification at ultra-low concentrations and unlocking new possibilities in neurology research and brain health management. Now, you can: • Measure CNS biomarkers across disease stages • Detect molecular changes earlier • Track biomarker dynamics in disease or recovery • Enhance sample stratification in research • Improveclinical trial enrollment and outcomes Learn more: https://lnkd.in/eq4Wc4tR #neurology #brainhealth #biomarkers